11/29/2021 | Press release | Distributed by Public on 11/28/2021 17:38

European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell CarcinomaApproval Based on[...]

• For Print
• November 29, 2021

• Full text

Please select the service you want to use:

• Newsvine
• Digg
• Delicious
• StumbleUpon
• Technorati
• Buzz
• Favorites
• Google Reader

 View original format